Cargando…

Certolizumab pegol has a different profile from other anti-TNFs, including golimumab, in a variety of in vitro assays

Detalles Bibliográficos
Autores principales:	Fossati, G, Nesbitt, A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007781/ http://dx.doi.org/10.1186/1479-5876-8-S1-P37

Ejemplares similares

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Reverse signalling of membrane TNF in human natural killer cells: a comparison of the effect of certolizumab pegol and other anti-TNF agents
por: Fossati, Gianluca, et al.
Publicado: (2011)

5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018)

PReS-FINAL-2250: Presentation of tuberculosis in patients using anti-TNFS drugs: report of 3 cases
por: Bica, BE, et al.
Publicado: (2013)

3. Certolizumab pegol for BehÇet's flare in pregnancy: a case report
por: Piper, Madeleine, et al.
Publicado: (2017)

Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga, Sriya, et al.
Publicado: (2014)

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
por: Barnes, Theresa, et al.
Publicado: (2007)

New biologics in the management of Crohn’s disease: focus on certolizumab pegol
por: Colombo, Elisabetta, et al.
Publicado: (2009)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
por: Blonski, Wojciech, et al.
Publicado: (2012)

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
por: Wade, Janet R., et al.
Publicado: (2015)

Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
por: Bailey, Kathryn, et al.
Publicado: (2020)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
por: Sharon, Yael, et al.
Publicado: (2020)

Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis
por: Meling, Maureen Tania, et al.
Publicado: (2021)

Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
por: Furst, D E, et al.
Publicado: (2015)

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
por: Hannech, Emna, et al.
Publicado: (2021)

Successful treatment of dissecting cellulitis with certolizumab pegol in a pregnant patient
por: Almuhanna, Nouf, et al.
Publicado: (2023)

Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index
por: Bykerk, Vivian P., et al.
Publicado: (2021)

Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
por: Dinesen, Lotte, et al.
Publicado: (2007)

Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2007)

Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritis
por: Rosa, J, et al.
Publicado: (2010)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
por: Soriano, Enrique R, et al.
Publicado: (2018)

Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
por: Dattola, Annunziata, et al.
Publicado: (2017)

Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
por: Marin, Josefina, et al.
Publicado: (2018)

Successful Certolizumab Pegol Treatment of Chronic Anterior Uveitis Associated with Psoriasis Vulgaris
por: Yamaguchi, Keiko, et al.
Publicado: (2018)

Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells
por: de Bourayne, Marie, et al.
Publicado: (2022)

Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling
por: Boyer, Jean Frédéric, et al.
Publicado: (2016)

The effects of anti–TNF agents on the expansion of T helper-type 17 cells driven by lipopolysaccharide-stimulated monocytes
por: Fossati, Gianluca, et al.
Publicado: (2012)

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
por: Roda, Giulia, et al.
Publicado: (2016)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
por: Acosta-Felquer, María Laura, et al.
Publicado: (2016)

Certolizumab Pegol-Induced Folliculitis-Like Lichenoid Sarcoidosis in a Patient with Rheumatoid Arthritis
por: Sakai, Hiroyuki, et al.
Publicado: (2017)

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
por: Vande Casteele, N., et al.
Publicado: (2017)

Correction to: Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
por: Dattola, Annunziata, et al.
Publicado: (2017)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

HLA‐C*06:02 allele can influence clinical efficacy of certolizumab pegol?
por: Dattola, Annunziata, et al.
Publicado: (2021)

Successful Use of Certolizumab Pegol for Refractory Psoriatic Arthritis Triggered by COVID-19 Infection
por: Ohmura, Shin-ichiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eiq44t27hn7bcvmiupt46md4um